临床肝病患者中庚型肝炎病毒(GBV-C/HGV)的感染

GBV-C/HGV Infection in Patients with HBV, HCV, HEV and nonA-E Hepatitis

本文应用抗-HGV酶联免疫法(EIA)和逆转录套式聚合酶链反应法(RT-PCR)检测150份乙型、120份丙型、15份戊型和49份非甲-戊型肝炎患者血清。结果显示:乙肝、丙肝、戊肝和非甲-戊型肝炎患者中抗-HGV抗体的阳性率分别为22.0％(33/150)、25.0％(30/120)、33.3％(5/15)和40.1％(20/49)。其中乙型、丙型、戊型和非甲-戊型肝炎的抗-HGV抗体阳性者中,HGV RNA的阳性率分别为58.3％(7/12)、60.0％(6/10)、40.0％(2/5)和45.5％(9/12)。说明GBV-C/HGV可与HBV、HCV或HEV合并感染,该病毒可能引起临床型肝炎。

Background/Aims: To investigate GBV-C/HGV infection in patients with HBV, HCV, HEV and non A-E hepatitis. Methods: The Anti-HGV EIA was developed with a synthetic peptide from NS3 region of HGV. Some of the anti-HGV positive samples were confirmed with RT-nPCR. Results: The anti-HGV positive rates in patients with HBV, HCV, HEV and non A-E hepatitis were 22% (33/150), 25% (30/120), 33.3% (5/15) and 40.1%(20/49), respectively. Conclusion: HGV may be one of the agents inducing clinical hepatitis.